Compare Bitwise Crypto Industry Innovators ETF (BITQ) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bitwise Crypto Industry Innovators ETF vs Medpace Holdings Inc — how do they compare? Bitwise Crypto Industry Innovators ETF trades at $22.92, while Medpace Holdings Inc trades at $599.79 (market cap $16.90B). The key difference: Medpace Holdings Inc is trading nearer its 52-week high, Bitwise Crypto Industry Innovators ETF nearer its low. Which is the better fit depends on your goals.
| BITQ | MEDP | |
|---|---|---|
Sector | Crypto-linked | Technology |
52-Week High | $30.43 | $620.59 |
52-Week Low | $16.74 | $393.42 |
Market Cap | — | $16.90B |
Enterprise Value | — | $16.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BITQ trades at $22.69, up 2.25% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock lacks disclosed financial ratios, limiting fundamental analysis. Recent news highlights institutional interest in crypto ETFs, though BITQ itself is a US stock with no direct crypto operations.
The outlook remains cautious due to weak technicals and absent fundamentals. Risks include market volatility and unverified financial health. Analyst consensus is unavailable, requiring deeper research into company filings for investment clarity.
MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.
Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bitwise Crypto Industry Innovators ETF
BITQ tracks companies at the forefront of the crypto economy, including miners, equipment suppliers, and financial service providers. It offers indirect exposure to the growth of the broader crypto ecosystem.
Read more on BITQ →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
